SEARCH

SEARCH BY CITATION

References

  • 1
    Billingham RE, Krohn PL, Medawar PB. Effect of cortisone on survival of skin homografts in rabbits. Br J Med 1951; 1: 1157.
  • 2
    Eason JD, Loss GE, Blazek J, Nair S, Mason AL. Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomised trial. Liver Transpl 2001; 7: 693.
  • 3
    Margarit C, Martinez-Ibañez V, Tormo R, Infante D, Iglesias J. Maintenance immunosuppression without steroids in pediatric liver transplantation. Transplant Proc 1989; 21: 2230.
  • 4
    Rolles K, Davidson BR, Burroughs AK. A pilot study of immunosuppressive monotherapy in liver transplantation: tacrolimus versus microemulsified cyclosporin. Transplantation 1999; 68: 1195.
  • 5
    Tisone G, Angelico M, Palmieri G, et al. A pilot study on the safety and effectiveness of immunosuppression without prednisone after liver transplantation. Transplantation 1999; 67: 1308.
  • 6
    Ringe B, Braun F, Schutz E, et al. A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. Transplantation 2001; 71: 508.
  • 7
    Reding R. Steroid withdrawal in liver transplantation. Benefits, risks and unanswered questions. Transplantation 2000; 70: 405.
  • 8
    Keteman NM. Steroid-free immunosuppression: balancing efficacy and toxicity. Liver Transpl 2001; 7: 698.
  • 9
    Stegall MD, Wachs ME, Everson GT, et al. Prednisone withdrawal 14 days after liver transplantation with mycophenolate. Transplantation 1997; 64: 1755.
  • 10
    Trotter JF, Wachs M, Bak T, Trouillot T, Stolpman N, Everson GT. Liver transplantation using sirolimus and minimal cortico-steroids (3-day taper). Liver Transpl 2001; 7: 343.
  • 11
    Lerut JP. Avoiding steroids in solid organ transplantation. Transpl Int 2003; 16: 213.
  • 12
    Lucey MR. Changing perspectives on the role of corticosteroids after liver transplantation. Liver Transplant Surg 1999; 5: S58.
  • 13
    Margarit C, Rimola A, Gonzalez-Pinto I, et al. Efficacy and safety of oral low-dose tacrolimus treatment in liver transplantation. Transpl Int 1998; 11(Suppl. 1): S260.
  • 14
    Figueras J, Bernardos A, Prieto M, et al. Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients. Transplant Proc 2002; 34: 1511.
  • 15
    Papatheodoridis GV, Barton SG, Andrew D, et al. Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppression regimens. Gut 1999; 45: 427.
  • 16
    Charlton M. The impact of advancing donor age on histologic recurrence of hepatitis C infection: The perils of ignored maternal advice. Liver Transpl 2003; 9: 535.
  • 17
    Adam R, Cailliez V, Majno P, et al. Normalised intrinsic mortality risk in liver transplantation: European Liver Transplant Registry Study. The Lancet 2000; 356: 621. Available at: http://www.eltr.org/publi/publications
  • 18
    Demetris AJ. Banff schema for grading liver allograft rejection. An International Consensus Document. Hepatology 1997; 75: 3.
  • 19
    Bilbao I, Charco R, Balsells J, et al. Risk factors for acute renal failure requiring dialysis after liver transplantation. Clin Transplant 1998; 12: 123.
  • 20
    Martell M, Gomez J, Esteban JI, et al. High-throughput real-time reverse transcription-PCR quantitation of hepatitis C virus RNA. J Clin Microbiol 1999; 37: 327.
  • 21
    Ishak K. Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J. Hepatol 1995; 22: 696.
  • 22
    van Duijnhoven EM, Boots JMM, Christiaans MHL, Stolk L, Undre NA, van Hooff JP. Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int 2003; 16: 712.
  • 23
    Prieto M, Berenguer M, Rayon JM, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29: 250.
  • 24
    Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after liver transplantation. Gastroenterology 2002; 122: 889.
  • 25
    Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680.
  • 26
    Boker KHW, Dalley G, Bahr MJ, et al. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology 1997; 25: 203.
  • 27
    Fasole CG, Netto GJ, Thomas M, et al. Corticosteroid (CS) maintenance and progression of hepatitis C histologic recurrence (HHCVR) in liver transplant recipients (OLT) at one and two years (Y) post transplant (TX): a dose-dependent benefit?. American Transplant Congress 2003; 558 (abstract).
  • 28
    Berenguer M. Natural history of recurrent hepatitis C. Liver Tanspl 2002; 8: S14.
  • 29
    Ghobrial RM, Steadman R, Gornbein J, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001; 234: 384.
  • 30
    Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000; 32: 1125.
  • 31
    Berenguer M, Crippin J, Gish R, et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003; 38: 34.
  • 32
    Burak KW, Kremers WK, Batts KP, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8: 362.
  • 33
    Wali MH, Heydtmann M, Harrison RF, Gunson BK, Mutimer DJ. Outcome of liver transplantation for patients infected by hepatitis C, including those infected by genotype 4. Liver Transpl 2003; 9: 796.
  • 34
    Otero J, Gavalda J, Murio JE, et al. Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation. Clin Infect Dis 1998; 26: 865.
  • 35
    Sheiner PA. Immunosuppression modifications in hepatitis C. Curr Opin Organ Transplant 2001; 6: 327.
  • 36
    Gregory TE. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 2002; 8(Suppl. 1): S19.